Skip to content

A randomized controlled trial on lipiodol intrauterine perfusion in women with unexplained repeated implantation failure

A randomized controlled trial on lipiodol intrauterine perfusion in women with unexplained repeated implantation failure

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024273
Enrollment
Unknown
Registered
2019-07-04
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Implantation Failure

Interventions

1:iodized oil intrauterine perfusion
2:none

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 40 years females; 2. With spontaneous menstrual cycle; 3. Experienced three or more fresh or thaw ET cycles, at least 4 high-quality embryos at cleavage stage or 3 high-quality blastocysts were transferred and no clinical pregnancy was achieved. 4. There were still high-quality frozen embryos available for implantation. 5. Agreement and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Known factors that exactly affects embryo implantation, such as severe uterine adhesions, septum uterus, uterine leiomyoma, endometrial polyps, endometrial hyperplasia, uterine malignant tumors, hydrosalpinx, Adenomyosis and endometriosis, et al; 2. Anyone couples with chromosome abnormalities, which were considered interfering the development and implantation of embryos by genetic consultants; or male with seriously weak sperms; 3. Patients with hyperthyroidism or hypersensitivity to iodine; 4. Any women amenorrhea but not yet ruled out pregnancy; 5. Severe heart and lung disease; uncontrolled hypertension, diabetes and obesity (BMI >= 28); 6. The body temperature was higher than 37.5 degree C during the last 3 days before perfusion,; 7. Patients with serious pregnancy-related diseases such as luteal dysfunction, thyroid dysfunction, polycystic ovary syndrome, reproductive tract infection, uterine or cervical bleeding; 8. Any conditions that was unstable or unlikely to compliance of the pregnancy. 9. Any patients that was inappropriate to be treated with this regimen.

Design outcomes

Primary

MeasureTime frame
Clinical Pregnency;live birth;

Secondary

MeasureTime frame
Chemical pregnancy;Miscarriage;

Countries

China

Contacts

Public ContactAiping Qin

The First Affiliated Hospital of Guangxi Medical University

aini02456@126.com+86 13977102456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026